Global Market Comments
April 25, 2025
Fiat Lux
Featured Trade:
(THE UNITED STATES OF DEBT)
(TLT)

Global Market Comments
April 25, 2025
Fiat Lux
Featured Trade:
(THE UNITED STATES OF DEBT)
(TLT)

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Mad Hedge Biotech and Healthcare Letter
April 24, 2025
Fiat Lux
Featured Trade:
(DIVIDEND HUNTING IN BEAR COUNTRY)
(BMY)

One stock in the pharmaceutical sector has been calling to me lately like a siren song amid market turbulence.
I'm talking about Bristol-Myers Squibb Co. (BMY), which has taken a beating in the March-April selloff but is dangling a forward estimated 5% dividend yield while generating a whopping 14% annual free cash flow — tops among the largest drug names.
I've been watching this one since January, when it first dipped below $52. Like a patient fisherman, I've been waiting for just the right moment to cast my line. That moment appears to be now, as BMY slides toward the $50 mark amid broader market jitters and sector rotation. It’s remarkable how often Wall Street throws the proverbial baby out with the bathwater during these periodic fits of selling.
The beauty of BMY is not just valuation. It’s historically proven itself as a financial bomb shelter — outperforming the S&P 500 in four major recessions since 1990.
During the 2020 pandemic, it returned 36% vs. the S&P’s 26%. In the Great Recession, it gained 13% while the broader market fell 16%.
During the 1990 Persian Gulf War recession, it delivered a jaw-dropping 76%.
And here’s one more kicker: BMY’s current 14% free cash flow yield is nearly 10% higher than equivalent cash investment yields — among the best “relative yields” it’s posted in 35 years.
On top of that, its 5%+ dividend towers over the S&P’s 1.3% and Big Pharma’s 3.65% median.
This is a rare setup where both the cash yield and the ability to sustain it align — a combination that’s very hard to beat in a defensive play.
Of course, no stock is bulletproof. BMY will need to navigate patent cliffs and increased regulatory scrutiny on drug pricing.
Wall Street is also pricing in little to no growth in the near term — and that’s probably fair. But the current setup suggests BMY could still outperform, especially if the S&P enters a decline in 2025.
This defensive mindset is why Warren Buffett and other veterans have been moving to abnormally extreme levels of cash since 2024. They're battening down the hatches while the financial seas are still relatively calm.
And speaking of smart investors, I had lunch last week at Tadich Grill with a hedge fund manager I’ve known for decades. When I mentioned I was looking for defensive plays, he immediately brought up BMY.
“What’s rare these days,” he said, “is a company with both a high dividend and the cash flow to actually back it up.” He then showed me his firm’s spreadsheets — stress-tested across recession scenarios back to Nixon — and BMY held firm.
Having run similar models myself (if not quite as colour-coded), I nodded in agreement.
At the current ~$50 share price, BMY’s free cash flow yield stands near 14%. That’s nearly 10% better than risk-free Treasury rates and more than double the Big Pharma peer group median of 6.15%.
So what could go wrong? A steeper summer selloff. Or an aggressive federal move to mandate drug pricing — a risk that’s always on the table, but rarely moves quickly. Supply chain issues, especially for ingredients sourced from China, are also worth watching.
That said, BMY has manufacturing facilities globally, and 71% of its revenue comes from the US. That gives it some insulation if trade tensions flare.
But here’s the thing: those risks hit all major pharma companies. BMY starts from a stronger base: better cash flow, better history, better defensive positioning.
My view? BMY is worth owning for its super-sized dividend and battle-tested resilience. I suggest you buy the dip.

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Global Market Comments
April 24, 2025
Fiat Lux
Featured Trade:
(TESTIMONIAL),
(MY FAVORITE PASSIVE/AGGRESSIVE PORTFOLIO)
(ROM), (UYG), (UCC), (DIG), (BIB)

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
The relationship between global trade policies and the technology sector is becoming increasingly intertwined. With tariffs on essential materials like steel and aluminum recently being implemented or proposed, the ripple effects extend far beyond construction and manufacturing. One area significantly impacted is the data center industry, which forms the backbone of the AI revolution. This article explores how rising costs for data center construction and maintenance, driven by tariffs, could indirectly influence AI processing and infrastructure development.
Data centers, the physical facilities housing servers and computing equipment, depend heavily on materials like steel and aluminum for their construction and operation. Steel is essential for building the structural framework, server racks, and enclosures, while aluminum is used for components like cooling systems, wiring, and casings. These materials ensure the physical stability and functionality of the centers, enabling uninterrupted service.
As AI technologies continue to advance, the demand for high-performance computing (HPC) systems, extensive storage solutions, and energy-efficient cooling mechanisms grows. This reliance on steel and aluminum makes data centers particularly vulnerable to price fluctuations in these materials.
Tariffs, which are taxes imposed on imported goods, can significantly increase the cost of steel and aluminum. For example:
The result is a surge in prices for raw materials needed to construct and upgrade data centers, thereby increasing the capital expenditure for companies in the tech industry.
Building a data center is already a capital-intensive process, often costing hundreds of millions of dollars. Tariffs on steel and aluminum can inflate these costs in several ways:
These increased expenses can lead to delays in new data center projects, as companies may require additional time to secure funding or reevaluate the feasibility of their investments.
The impact of tariffs is not limited to initial construction. Data centers require regular maintenance and upgrades, often involving steel and aluminum components:
These operational challenges can hinder a company's ability to maintain its infrastructure, reducing its capacity to support AI workloads.
AI systems, from natural language processing to autonomous vehicles, rely on the computational power provided by data centers. When tariffs drive up data center costs, the following indirect effects on AI processing can be observed:
Data centers are continually evolving to become more energy-efficient and environmentally friendly. However, tariffs can create roadblocks in this journey:
These challenges are particularly concerning given the growing energy demands of AI technologies, which already contribute to the carbon footprint of the tech industry.
Tariffs also affect the global supply chain for steel and aluminum, introducing additional complexities for data center operators:
These dynamics further underscore the interconnectedness of global trade policies and the AI ecosystem.
Despite these challenges, companies can adopt strategies to mitigate the impact of tariffs on data centers and AI infrastructure:
These proactive measures can help companies navigate the complexities of tariffs while continuing to invest in AI development.
The imposition of tariffs on materials like steel and aluminum presents significant challenges for the data center industry, indirectly affecting AI processing and infrastructure. By driving up construction and maintenance costs, tariffs could slow the growth of AI technologies, limit innovation, and disrupt global supply chains.
However, with strategic planning and collaboration, companies can mitigate these impacts and ensure the continued advancement of AI. As the relationship between trade policies and technology evolves, the industry must remain adaptable and forward-thinking to overcome these obstacles.
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.
